Royalty Pharma plc (FRA:RPD)

Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of EUR 16.41 billion. The enterprise value is 26.23 billion.

Market Cap	16.41B
Enterprise Value	26.23B

Important Dates

The last earnings date was Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	Feb 20, 2026

Share Statistics

Current Share Class	428.42M
Shares Outstanding	n/a
Shares Change (YoY)	-4.99%
Shares Change (QoQ)	-0.65%
Owned by Insiders (%)	11.56%
Owned by Institutions (%)	84.37%
Float	376.42M

Valuation Ratios

The trailing PE ratio is 24.99 and the forward PE ratio is 6.82.

PE Ratio	24.99
Forward PE	6.82
PS Ratio	8.10
PB Ratio	1.98
P/TBV Ratio	3.47
P/FCF Ratio	n/a
P/OCF Ratio	7.74
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	39.95
EV / Sales	12.99
EV / EBITDA	19.40
EV / EBIT	19.45
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.92.

Current Ratio	2.40
Quick Ratio	2.39
Debt / Equity	0.92
Debt / EBITDA	5.74
Debt / FCF	n/a
Interest Coverage	5.07

Financial Efficiency

Return on equity (ROE) is 13.20% and return on invested capital (ROIC) is 5.32%.

Return on Equity (ROE)	13.20%
Return on Assets (ROA)	5.15%
Return on Invested Capital (ROIC)	5.32%
Return on Capital Employed (ROCE)	8.21%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	20.26M
Profits Per Employee	6.57M
Employee Count	100
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.97% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+19.97%
50-Day Moving Average	34.21
200-Day Moving Average	31.63
Relative Strength Index (RSI)	57.48
Average Volume (20 Days)	42

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.52

Income Statement

In the last 12 months, Royalty Pharma had revenue of EUR 2.03 billion and earned 656.62 million in profits. Earnings per share was 1.52.

Revenue	2.03B
Gross Profit	2.28B
Operating Income	1.33B
Pretax Income	1.13B
Net Income	656.62M
EBITDA	1.33B
EBIT	1.33B
Earnings Per Share (EPS)	1.52

Balance Sheet

The company has 542.96 million in cash and 7.64 billion in debt, with a net cash position of -7.10 billion.

Cash & Cash Equivalents	542.96M
Total Debt	7.64B
Net Cash	-7.10B
Net Cash Per Share	n/a
Equity (Book Value)	8.27B
Book Value Per Share	12.87
Working Capital	759.61M

Cash Flow

Operating Cash Flow	2.12B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 112.44%, with operating and profit margins of 65.58% and 32.42%.

Gross Margin	112.44%
Operating Margin	65.58%
Pretax Margin	55.68%
Profit Margin	32.42%
EBITDA Margin	65.74%
EBIT Margin	65.58%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.77, which amounts to a dividend yield of 2.09%.

Dividend Per Share	0.77
Dividend Yield	2.09%
Dividend Growth (YoY)	-2.39%
Years of Dividend Growth	6
Payout Ratio	49.06%
Buyback Yield	4.99%
Shareholder Yield	7.08%
Earnings Yield	4.00%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.51
Piotroski F-Score	6